Kornimate/medical-research-clean huggingface dataset:
effect of the adjunctive ivb before prp

Conditions: Diabetic Retinopathy

Summary: this study is to investigate the effect of adjunctive intravitreal bevacizumab (ivb) before panretinal photocoagulation (prp) compared with only prp on central macular thickness and retinal nerve fiber layer thickness in patients with severe diabetic retinopathy without macular edema.

this prospective randomized study included 30 patients (60 eyes) with severe nonproliferative diabetic retinopathy or non-high-risk proliferative diabetic retinopathy. they had weekly prp treatments in 3 sessions and they were randomly assigned to ivb group who had adjunctive ivb within 1 week before first prp and control group who had only prp. cmt, rnfl, and best-corrected visual acuity (bcva) were measured

Eligibility criteria:
inclusion criteria: * patients with severe npdr or early pdr without macular edema * best-corrected visual acuity (bcva) of 20/25 or better * patients who were followed up for at least 6 months after the first prp. exclusion criteria: * patients with retinal or choroidal diseases except diabetic retinopathy * contraindications to fluorescein angiography (fa) or bevacizumab * patients who had previous treatments including anti-angiogenic medications and laser photocoagulation * patients with previous vitrectomy * patients with uncontrolled hypertension, a recent myocardial infarction or cerebral vascular accidents.

Keywords: central macular thickness
data analysis for drug repurposing for effective alzheimer's medicines (dream)- dihydropyridine calcium channel blockers versus hydrochlorothiazide

Conditions: Hypertension

Summary: this study aims to evaluate the comparative risk of dementia/alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

this is a non-randomized, non-interventional study that is part of the dream study of brigham and women's hospital. dream is led by dr. madhav thambisetty, md, phd, chief of the clinical and translational neuroscience section, laboratory of behavioral neuroscience, national institute on aging (nia) intramural research program. this study aims to evaluate the comparative risk of dementia/alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication using healthcare claims data.

Eligibility criteria:
please see https://docs.google.com/spreadsheets/d/1vlyy3zcxorp0th7yv8rsoeggso6wq0vyejq-6klsst8/edit?usp=sharing or appendix a for full code and algorithm definitions. medicare timeframe: 2008 to 2018 (end of data availability). inclusion criteria: * 1. aged \> 65 years on the index date * 2. enrollment in medicare part a, b, and d with no hmo coverage for 365 days prior to and including cohort entry date * 3. at least two claims with hypertension diagnosis recorded in 365 days prior to cohort entry date exclusion criteria: * 1. prior history of dementia measured anytime prior to cohort entry date * 2. prior use of dihydropyridine ccbs, hydrochlorothiazide, or other antihypertensives anytime prior to cohort entry date
expanded access program (eap) designed to provide access to botensilimab and balstilimab before regulatory approval

Conditions: Colorectal Cancer (CRC); Pancreatic Cancer; Non-Small Cell Lung Cancer (NSCLC); Hepatocellular Carcinoma (HCC); Melanoma; Sarcoma; Ovarian Cancer; Prostate Cancer

Summary: this is an expanded access program (eap) designed to provide access to botensilimab and balstilimab prior to drug registration by the applicable local regulatory agency. a medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

this eap is available for indications where there is reasonable scientific basis for use. availability will depend on territory eligibility.

Eligibility criteria:
key inclusion criteria: * the patient's disease is serious or life-threatening. * the patient has undergone appropriate standard treatments; there are no comparable or satisfactory alternative treatments for the disease or condition; the treatment is adjunct to an existing treatment option, and the treatment is not medically contra-indicated. * sufficient efficacy and safety evidence exists to make a benefit-risk analysis consistent with this policy and the potential patient benefit justifies any potential risks of treatment. * sufficient clinical data are available to identify an appropriate dose and treatment duration. * the patient's treating physician and qualified medical personnel at agenus agree there is sufficient evidence to assume the potential benefit to the patient justifies potential risks. * the patient is not eligible for participation in an ongoing clinical trial of the investigational medicine, including lack of access due to geographic limitations. * expanded access will not adversely impact any clinical development program, in particular, the conduct of a pivotal clinical trial that is required for regulatory approval. * the request must be made by the patient's treating physician. note: other defined inclusion/exclusion criteria may apply.

Keywords: compassionate use early access expanded access managed access pre-approval access special access named patient program (npp)
anti-cd19 car-t therapy combine with hsct to treat mrd+ b-cell malignancies

Conditions: Acute Lymphoblastic Leukemia; B Cell Lymphoma

Summary: for micro residual disease (mrd) positive patients who have undergone at least 2 cycles chemotherapies for their cd19+ b-cell malignancies, there would be much more risks for them to receive hematological stem cell transplantation (hsct) than mrd- patients. in order to reduce hsct-related adverse events for these kind of patients, investigators plan to conduct car-t therapies on them first to make them achieve mrd- statuses, and then transfer them to hsct.

in order to improve prognoses for mrd+ patients who have undergone at least 2 cycles chemotherapies, patients will receive car-t therapy before hsct, once they achieve mrd- remissions, they will subsequently receive hsct if there are no contraindications.

Eligibility criteria:
inclusion criteria: 1. the patient is pathologically and histologically confirmed as cd19 + b cell tumors, and has no effective treatment options currently, such as chemotherapy or autologous hematopoietic stem cell transplantation (auto-hsct); or patients voluntarily choose cd19 car-t cells as a first treatment; 2. the patient is mrd+ (\<10%) after at least two cycles of chemotherapies. 3. b cell hematological malignancies include the following three categories: * b-cell acute lymphocytic leukemia (b-all); * indolent b-cell lymphoma (cll, fl, mzl, lpl); * aggressive b-cell lymphoma (dlbcl, bl, mcl); 4. \< 70 years old; 5. expected survival time \> 6 months; 6. female patients around childbearing age, negative pregnancy test before trial, and agreed to take effective contraceptive measures during the trial until the last visit; 7. voluntarily participate in this experiment and sign informed consent by themselves, or legally authorized representative. exclusion criteria: 1. with a history of allo-hsct; 2. with a history of epilepsy or other central nervous system diseases; 3. the presence of clinically significant cardiovascular disease, such as uncontrolled or symptomatic arrhythmias, congestive heart failure or myocardial infarction within recent six months, or heart disease with cardiac function in any grade 3 (moderate) or 4 ( severe) (according to the new york heart association (nyha) functional classification system); 4. pregnant or lactating women (safety of this therapy for the unborn child is unknown); 5. not curable active infection; 6. patients with active hepatitis b or hepatitis c virus infection; 7. combined use of systemic steroids within two weeks (except use of inhaled steroid recently or currently); 8. using product of gene therapy before; 9. creatinine\> 2.5 mg / dl (221.0 umol/l); alt / ast\> 3 x the normal amount; bilirubin\> 2.0 mg / dl (34.2 umol/l); 10. patients suffering from other uncontrolled diseases, and researchers believe that the patient is not suitable for trial; 11. patients with hiv-infection; 12. any situation that may increase the risk of patients or interfere with test results.
effects of desensitizing dentifrices on the reduction of pain sensitivity caused by in-office dental whitening

Conditions: Tooth Whitening; Sensitivity

Summary: introduction: the pain sensitivity associated with whitening is the main problem reported by patients during dental whitening, and the use of desensitizing dentifrices is an alternative for the treatment of sensitivity. objective: to evaluate clinically the influence of desensitizing dentifrices applied through a plastic tray, reducing the pain sensitivity and color variation caused by the technique of in-office dental whitening, through a controlled double-blind clinical study. methods: a longitudinal prospective study was conducted with 48 individuals, 18 years and 30 years of age, without gender distinction, who underwent in-office dental whitening using 35% hydrogen peroxide (whiteness hp, fgm, joinville , sc, brazil) in three clinical sessions with a one-week interval between them. the volunteers used in the night for each bleaching session a plastic tray for 4 hours containing one of the dentifrices related to the experimental groups: group 1 (control) - sucralose (s) (biotype - manipulation pharmacy); group 2 (active control) - sodium fluoride (fs) with 1450ppm of fluorine (close up triple, unilever); group 3 - arginine, calcium carbonate (acc) and sodium monofluorophosphate with 1450 ppm fluorine (colgate sensitive pro-relief, colgate-palmolive); group 4 - 5% potassium nitrate (np) and sodium fluoride with 1450 ppm fluorine (sensodyne pro-enamel, glaxosmithkline). the evaluation of the sensitivity associated with the times of use of the plastic tray in the first session (s1: sensitivity before the tray, s2: sensitivity after the tray), in the second session (s3: sensitivity before the tray, s4: in the third session (s5: sensitivity before the tray, s6: sensitivity after the tray) used the analog numerical scale with scores from 0 to 10 and for the color evaluation the spectrophotometer (easyshade, vident, brea, ca, obtaining the data that were used in the cielab system. the data were submitted to the multivariate analysis of variance (manova) with repeated measurements and lambda wilks test with a 5% probability level to differentiate the groups. in addition, the factorial variance analysis (anova) in one criterion was applied. values of p \<0.05 were considered statistically significant.


Eligibility criteria:
inclusion criteria: * age of 18 years or older * good oral and general health * hygid anterior tooth with color shade higher than a2 on the vita classic scale (vita zahnfabrink, bad säckingen, germany). exclusion criteria: * smoking, pregnancy or breastfeeding * previous dental whitening * para-functional habits * dentin sensitivity * anterior tooth with restorations and carious lesions * non-vital discoloration * unsatisfactory restorations

Keywords: tooth whitening dentifrice sensitivity
assessment of the development of postoperative persistent postoperative pain

Conditions: Opioid Use; Post Operative Pain; Chronic Pain

Summary: during the postoperative period, it is possible to observe the development of acute pain, which lasts no longer than a week after surgery. however, sometimes some patients see the prolongation of this pain beyond the healing time of the tissue, turning into a chronic condition. persistent postoperative pain is a disease with a complex and still unknown etiology, affecting between 5 and 75% of the population. the development of persistent postoperative pain is a rather important issue since the physician managing the patient must on the one hand ensure adequate analgesia, and on the other hand, minimize the risk of continued opioid use in the case of chronicization. in a study conducted analyzing the prevalence of persistent postoperative pain in various surgeries it was seen to occur more frequently in limb amputation (prevalence \>85%), thoracotomy (prevalence 48%), knee arthroplasty (prevalence 44%), laminectomies, and spinal arthrodesis (prevalence 5-46%), and hip replacement (prevalence 27%) making this type of pain more frequent in the patient undergoing orthopedic surgery. as the mechanisms behind its development have not yet been fully clarified, efforts to study the clinical factors associated with the onset of this pathology have been attempted. as there is no way in the literature to stratify the risk of the population in order to prevent the development of postoperative pain, based on the variables reported by different studies, it was decided to administer in patients referred to the orthopedics and traumatology 1 u and orthopedics and traumatology 3 u department at the orthopedic trauma center of turin questionnaires to assess the development of chronic pain for screening purposes and to contribute to the improvement of the long-term management of these patients in the postoperative period.


Eligibility criteria:
inclusion criteria: * patients undergoing orthopedic surgery considered at high risk of developing persistent postoperative pain (i.e. knee prothesic surgery, hip prothesic surgery, spine fusion surgery) exclusion criteria: * patients undergoing redo prothesic surgery * trauma patients

Keywords: postoperative pain opioid naive opioid tolerant orthopedic surgery
effect of fan-7 in uc activity

Conditions: Inflammatory Bowel Disease; Ulcerative Colitis

Summary: introduction: inflammatory bowel disease (ibd) refers to two chronic diseases that cause intestinal inflammation, ulcerative colitis (uc) and crohn's disease (cd). the conventional treatment is not effective; therefore, alternative therapies may be effective specially in uc patients. fatty acid (fa) may have a beneficial effect on some uc patients. the increasing incidence and prevalence of uc and ineffective treatments in some patients, allows search coadjuvant therapies. objective: quantification of differences between patients with and without fa. methods: in two groups of patients with uc is administered fa and placebo. we will measure the changes clinical, endoscopic and histological in both groups, before and after treatment.


Eligibility criteria:
inclusion criteria: * patients with a histopathologically confirmed diagnosis of uc. * with mild and moderate disease. * patients treated with only doses of 5-aminosalicylates (5-asa) * bmi, 18 to 34.9 kg/m2 * born in mexico the last two generations * each patient will be asked to sign and date the consent form, to indicate that you agree to participate. exclusion criteria: * patient with associated diseases such as diabetes mellitus, hypertension, dyslipidemia, atherosclerosis and malabsorption syndrome. * with autoimmune diseases (lupus, hiv, cancer and hepatitis), colitis (infectious, post-radiation, post-drug, indeterminate) and crohn's disease. * if the patient use drugs that inhibit fat absorption. * patients after partial or total resection of stomach or small intestine. * steroid users. * patients in remission histology, clinical and endoscopic. * patients treated with fan-3,6 or 9.

Keywords: palmitoleic acid ulcerative colitis
epinephrine dose: optimal versus standard evaluation trial

Conditions: Cardiac Arrest, Out-Of-Hospital; Sudden Cardiac Arrest; Ventricular Fibrillation; Ventricular Tachycardia-Pulseless

Summary: the objective of this randomized controlled trial is to evaluate the effectiveness of a low cumulative dose of epinephrine compared to a standard cumulative dose of epinephrine during resuscitation from ventricular fibrillation (vf) or ventricular tachycardia (vt) in adult out-of-hospital cardiac arrest (ohca) patients.

this study is designed as a prospective, multicentre, single-blinded randomized controlled trial (rct) where eligible ohca patients are randomized to receive a low cumulative dose of epinephrine (low dose epinephrine, up to 2mg total) or a standard cumulative dose of epinephrine (standard dose epinephrine, up to 6mg total) in a 1:1 fashion. eligible ohca patients will be treated by paramedics who will initiate cardiopulmonary resuscitation (cpr) and the delivery of defibrillation shocks per paramedic agencies' treatment protocols. after one defibrillation and when feasible, paramedics will establish peripheral intravenous (iv) access, and patients will be randomly allocated to either the low dose or standard dose treatment arm. epinephrine doses (according to treatment assignment) will be administered every 3-5 minutes, based on current guidelines and paramedic protocols, until the first return of spontaneous circulation (rosc) is achieved or if resuscitation has been terminated by the base hospital physician. other medications (e.g. antiarrhythmics, magnesium, beta blockers) and interventions (e.g. intubation) may be interposed as required. follow-up will take place using a combination of administrative databases (e.g. the discharge abstract database and the national ambulatory care reporting system) and telephone interviews. this rct will evaluate a fundamental change in the treatment of ohca. the investigators hypothesize that a low cumulative dose of epinephrine will improve patient survival to hospital discharge compared to a standard cumulative dose of epinephrine. please feel free to contact epidose@unityhealth.to for further information.

Eligibility criteria:
inclusion criteria: * out-of-hospital cardiac arrest treated by paramedics * initial recorded cardiac rhythm of vf or pulseless vt, or, aed shock on first analysis administered or witnessed by ems (paramedic or fire) * established intravenous vascular access exclusion criteria: * known or apparent age \<18 years * initial recorded cardiac rhythm of vf or pulseless vt, or, aed shock on first analysis administered or confirmed by paramedics * cardiac arrest due to an obvious non-cardiac primary cause (e.g. blunt or penetrating trauma, exsanguination, burns, drug overdose, drowning, anaphylaxis, sudden asphyxiation, etc.) * administration of intramuscular, endotracheal tube, or intraosseous epinephrine * prisoners or persons in police custody * known allergy or sensitivity to epinephrine

Keywords: out-of-hospital cardiac arrest sudden cardiac arrest epinephrine randomized controlled trial
cannabidiol for graft versus host disease (gvhd) prophylaxis in allogeneic stem cell transplantation

Conditions: Graft Versus Host Disease

Summary: graft versus host disease (gvhd) is one of the major causes of death in patients undergoing allogeneic hematopoietic cell transplantation. despite prophylactic measures, the incidence of acute gvhd is estimated at 40-60% among patients receiving transplant from hla-identical sibling donors, and may even reach 75% in patients receiving hla-matched unrelated transplants. more effective prevention and treatment strategies are needed. the immunomodulatory and anti-inflammatory properties of cannabinoids have been shown in animal models of various inflammatory diseases including multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis. cannabidiol is a major non-psychoactive cannabinoid, which has potent anti-inflammatory and immunosuppressive effects. as such, it may reduce the incidence and severity of gvhd after allogeneic stem cell transplantation.


Eligibility criteria:
inclusion criteria: 1. patients undergoing allogeneic stem cell transplantation. 2. no previous history of psychosis. - exclusion criteria: 1. previous history of psychosis. 2. consumption of cannabis during the last 2 moths before transplantation. -

Keywords: cannabidiol gvhd allogeneic transplantation prophylaxis
a study of ramucirumab plus pembrolizumab in participants with gastric or gej adenocarcinoma, nsclc, transitional cell carcinoma of the urothelium, or biliary tract cancer

Conditions: Gastric Adenocarcinoma; Adenocarcinoma of the Gastroesophageal Junction; Non-small Cell Lung Cancer; Carcinoma, Transitional Cell; Biliary Tract Cancer

Summary: the main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (gej) adenocarcinoma, non-small cell lung cancer (nsclc), transitional cell carcinoma of the urothelium, or biliary tract cancer (btc).


Eligibility criteria:
inclusion criteria: * metastatic disease or locally advanced, unresectable disease. * has histopathologically confirmed gastric or gej adenocarcinoma with documented disease progression after 0-2 prior lines of systemic therapy * has histopathologically confirmed nonsquamous or squamous nsclc with documented disease progression after 0-3 prior lines of systemic therapy * has histopathologically confirmed transitional cell carcinoma of the urothelium (bladder, urethra, or renal pelvis) with documented disease progression after 1-3 prior lines of systemic therapy * has histologically confirmed biliary tract adenocarcinoma with documented progression after 1-2 prior lines of systemic therapy * availability of tumor tissue for biomarker analysis from a newly obtained core or excisional biopsy or willing to undergo a tumor biopsy. for first line nsclc participants only, pd-l1 expression should be 1% or higher. * have an eastern cooperative oncology group performance status of 0 or 1. * has adequate organ function. * have an anticipated life expectancy of ≥3 months. exclusion criteria: * have known brain metastases. * has received ≥3 lines of prior systemic therapy for gastric or gej adenocarcinoma and btc or ≥4 lines for nsclc or urothelial cancer. * has active autoimmune disease. * known human immunodeficiency virus (hiv) infection. * known active hepatitis b or hepatitis c infection. * has received any previous systemic therapy targeting vascular endothelial growth factor (vegf) or vegf receptor, or programmed death (pd) 1 or pd-ligand 1/2 signaling pathways. * have received a live vaccine within 30 days prior to enrollment. seasonal flu vaccines that do not contain live virus are permitted. * have had a serious or non-healing wound, ulcer, or bone fracture within 28 days prior to enrollment. * have an elective or a planned major surgery during the course of the trial or has undergone major surgery within 28 days prior to enrollment.

Keywords: immuno-oncology vascular endothelial growth factor (vegf) angiogenesis pd-1 carcinoma of the bladder carcinoma of the urethra carcinoma of the ureter carcinoma of the renal pelvis carcinoma of the biliary tract
effect of hiv protease inhibitor drugs on glucose and insulin metabolism

Conditions: HIV Infections

Summary: this study examined the effects of two commonly prescribed hiv drugs on the way the body metabolizes glucose, insulin and fat.


Eligibility criteria:
inclusion criteria: * healthy volunteers
clinical outcomes of endoscopic resection for treating whyx lesion

Conditions: WHYX Lesion; Extremely Well Differentiated Intestinal-type Adenocarcinoma

Summary: endoscopically, whyx cancers demonstrated a vague extent of tumor spread due to pale color changes in both the background atrophic and metaplastic gastric mucosa. however, the clinical outcomes of whyx cancers after endoscopic resection are unknown. the aim of this study was to evaluate clinical outcomes of whyx cancers after endoscopic resection.


Eligibility criteria:
inclusion criteria: * from january 2009 to december 2010 enrolled 872 patients with egc exclusion criteria: * egc with regional lymph node metastasis in radiologic finding endoscopically suspicious submucosal invasion

Keywords: whyx lesion endoscopic resection complete resection complete resection rate endoscopic feature average size discrepancy